Video

Dr. Kumar on the Rationale Behind the ENDURANCE Trial in Newly Diagnosed Myeloma

Author(s):

Shaji Kumar, MD, discusses the rationale behind the phase 3 ENDURANCE trial, which is comparing carfilzomib, lenalidomide, and dexamethasone with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Shaji Kumar, MD, a hematologist with Mayo Clinic, discusses the rationale behind the phase 3 ENDURANCE trial, which is comparing carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd) in newly diagnosed multiple myeloma.

It is known that a SWOG phase 3 trial demonstrated that VRd improves survival outcomes for this patient population and, as such, it has become the standard of care, says Kumar. Additionally, phase 2 trial results have demonstrated that KRd can be highly effective in the newly diagnosed setting, adds Kumar.

As such, investigators in ENDURANCE, investigators wanted to see how KRd would fare in a head-to-head setting and whether KRd would improve progression-free survival compared with VRD in patients with newly diagnosed disease, Kumar concludes.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Michael R. Bishop, MD
Mansi R. Shah, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
C. Ola Landgren, MD, PhD
Robert M. Rifkin, MD
David Samuel Dicapua Siegel, MD
Marcella Ali Kaddoura, MD
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.